Abstract
Objective: To describe the parental experience of recruitment and assess differences between parents who participated and those who declined to enroll in a neonatal clinical trial. Study design: This was a survey conducted at 12 US neonatal intensive care units of parents of infants who enrolled in the High-dose Erythropoietin for Asphyxia and encephaLopathy (HEAL) trial or who were eligible but declined enrollment. Questions assessed 6 factors of the parental experience of recruitment: (1) interactions with research staff; (2) the consent experience; (3) perceptions of the study; (4) decisional conflict; (5) reasons for/against participation; and (6) timing of making the enrollment decision. Results: In total, 269 of 387 eligible parents, including 183 of 242 (75.6%) of those who enrolled their children in HEAL and 86 of 145 (59.3%) parents who declined to enroll their children in HEAL, were included in analysis. Parents who declined to enroll more preferred to be approached by clinical team members rather than by research team members (72.9% vs 49.2%, P =.005). Enrolled parents more frequently reported positive initial impressions (54.9% vs 10.5%, P <.001). Many parents in both groups made their decision early in the recruitment process. Considerations of reasons for/against participation differed by enrollment status. Conclusions: Understanding how parents experience recruitment, and how this differs by enrollment status, may help researchers improve recruitment processes for families and increase enrollment. The parental experience of recruitment varied by enrollment status. These findings can guide future work aiming to inform optimal recruitment strategies for neonatal clinical trials.
Original language | English |
---|---|
Pages (from-to) | 143-149.e3 |
Journal | Journal of Pediatrics |
Volume | 239 |
DOIs | |
State | Published - Dec 2021 |
Keywords
- decisional conflict
- enrollment decision-making
- research participation
Fingerprint
Dive into the research topics of 'Parental Enrollment Decision-Making for a Neonatal Clinical Trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Parental Enrollment Decision-Making for a Neonatal Clinical Trial. / Weiss, Elliott Mark; Guttmann, Katherine F.; Olszewski, Aleksandra E. et al.
In: Journal of Pediatrics, Vol. 239, 12.2021, p. 143-149.e3.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Parental Enrollment Decision-Making for a Neonatal Clinical Trial
AU - Weiss, Elliott Mark
AU - Guttmann, Katherine F.
AU - Olszewski, Aleksandra E.
AU - Magnus, Brooke E.
AU - Li, Sijia
AU - Kim, Scott Y.H.
AU - Shah, Anita R.
AU - Juul, Sandra E.
AU - Wu, Yvonne W.
AU - Ahmad, Kaashif A.
AU - Bendel-Stenzel, Ellen
AU - Isaza, Natalia A.
AU - Lampland, Andrea L.
AU - Mathur, Amit M.
AU - Rao, Rakesh
AU - Riley, David
AU - Russell, David G.
AU - Salih, Zeynep N.I.
AU - Torr, Carrie B.
AU - Weitkamp, Joern Hendrik
AU - Anani, Uchenna E.
AU - Chang, Taeun
AU - Dudley, Juanita
AU - Flibotte, John
AU - Havrilla, Erin M.
AU - O'Kane, Alexandra C.
AU - Perez, Krystle
AU - Stanley, Brenda J.
AU - Shah, Seema K.
AU - Wilfond, Benjamin S.
N1 - Funding Information: We thank the parents who participated in our survey study, both those who enrolled and those who declined participation in HEAL. We thank the research team for the parent HEAL trial and NINDS for funding the parent HEAL trial. We thank the members of the University of Washington NICU Family Advisory Council. We thank Tira Oskoui, BS, Children’s National Hospital, and Kaeley Stout, BA, Seattle Children’s Research Institute, for literature review assistance. We thank Deepthi Nair, MS, formerly with Seattle Children’s Hospital now with Avalyn Pharma for assistance with REDCap creation. We would like to acknowledge assistance with survey administration and other administrative support from: Anthony Barton, Washington University School of Medicine ; Andrea DeMarsh, MS, Children’s National Hospital ; Isabella Esposito, BS, University of Washington School of Medicine ; Sheila Ganti, PhD, Seattle Children’s Hospital ; Amy M. Goodman, PhD, Fernando Gonzalez, MD, and Kelleen Nelson, BS, University of California, San Francisco ; Alissa Jorgenson, BA, and Catherine Worwa, BS, Children’s Minnesota ; Brenda B. Poindexter, MD, MS, Cincinnati Children’s and University of Cincinnati College of Medicine ; Theresa J. Rogers, RN, Vanderbilt University Medical Center ; Vivek Vijayamadhavan, MD, and Charmaine M. Kathen, DNP, Pediatrix Medical Group San Antonio Texas; and Danielle D. Weinberg, MPH, Children’s Hospital of Philadelphia. None of the above non-author contributors were provided monetary compensation. Any industry relation or conflicts of interest are reported above. We have obtained written permission to include their names in the Acknowledgement section of this manuscript. Tablets were loaned by Seattle Children’s Hospital’s Digital Health and Information Technology Departments and the Center for Child Health, Behavior and Development. Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington. 19 , 26 REDCap is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources. REDCap at the University of Washington is supported by Institute of Translational Health Science grant support ( UL1 TR002319 , KL2 TR002317 , and TL1 TR002318 from National Center for Advancing Translational Sciences / National Institutes of Health ). Funding Information: Funded by Seattle Children's Hospital Center for Clinical & Translational Research Clinical Research Scholars Program with additional support from Children's Minnesota Research Grant Program and University of Washington Neonatal Bioresearch Fund. The funders had no control over design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. J-H.W. reports receiving fees as a consultant for Roche Diagnostics Corporation to help with development of a neonatal sepsis marker. The other authors declare no conflicts of interest.We thank the parents who participated in our survey study, both those who enrolled and those who declined participation in HEAL. We thank the research team for the parent HEAL trial and NINDS for funding the parent HEAL trial. We thank the members of the University of Washington NICU Family Advisory Council. We thank Tira Oskoui, BS, Children's National Hospital, and Kaeley Stout, BA, Seattle Children's Research Institute, for literature review assistance. We thank Deepthi Nair, MS, formerly with Seattle Children's Hospital now with Avalyn Pharma for assistance with REDCap creation. We would like to acknowledge assistance with survey administration and other administrative support from: Anthony Barton, Washington University School of Medicine; Andrea DeMarsh, MS, Children's National Hospital; Isabella Esposito, BS, University of Washington School of Medicine; Sheila Ganti, PhD, Seattle Children's Hospital; Amy M. Goodman, PhD, Fernando Gonzalez, MD, and Kelleen Nelson, BS, University of California, San Francisco; Alissa Jorgenson, BA, and Catherine Worwa, BS, Children's Minnesota; Brenda B. Poindexter, MD, MS, Cincinnati Children's and University of Cincinnati College of Medicine; Theresa J. Rogers, RN, Vanderbilt University Medical Center; Vivek Vijayamadhavan, MD, and Charmaine M. Kathen, DNP, Pediatrix Medical Group San Antonio Texas; and Danielle D. Weinberg, MPH, Children's Hospital of Philadelphia. None of the above non-author contributors were provided monetary compensation. Any industry relation or conflicts of interest are reported above. We have obtained written permission to include their names in the Acknowledgement section of this manuscript. Tablets were loaned by Seattle Children's Hospital's Digital Health and Information Technology Departments and the Center for Child Health, Behavior and Development. Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington.19,26 REDCap is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for data integration and interoperability with external sources. REDCap at the University of Washington is supported by Institute of Translational Health Science grant support (UL1 TR002319, KL2 TR002317, and TL1 TR002318 from National Center for Advancing Translational Sciences/National Institutes of Health). Funding Information: Funded by Seattle Children’s Hospital Center for Clinical & Translational Research Clinical Research Scholars Program with additional support from C hildren’s Minnesota Research Grant Program and University of Washington Neonatal Bioresearch Fund . The funders had no control over design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. J-H.W. reports receiving fees as a consultant for Roche Diagnostics Corporation to help with development of a neonatal sepsis marker. The other authors declare no conflicts of interest. Publisher Copyright: © 2021 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - Objective: To describe the parental experience of recruitment and assess differences between parents who participated and those who declined to enroll in a neonatal clinical trial. Study design: This was a survey conducted at 12 US neonatal intensive care units of parents of infants who enrolled in the High-dose Erythropoietin for Asphyxia and encephaLopathy (HEAL) trial or who were eligible but declined enrollment. Questions assessed 6 factors of the parental experience of recruitment: (1) interactions with research staff; (2) the consent experience; (3) perceptions of the study; (4) decisional conflict; (5) reasons for/against participation; and (6) timing of making the enrollment decision. Results: In total, 269 of 387 eligible parents, including 183 of 242 (75.6%) of those who enrolled their children in HEAL and 86 of 145 (59.3%) parents who declined to enroll their children in HEAL, were included in analysis. Parents who declined to enroll more preferred to be approached by clinical team members rather than by research team members (72.9% vs 49.2%, P =.005). Enrolled parents more frequently reported positive initial impressions (54.9% vs 10.5%, P <.001). Many parents in both groups made their decision early in the recruitment process. Considerations of reasons for/against participation differed by enrollment status. Conclusions: Understanding how parents experience recruitment, and how this differs by enrollment status, may help researchers improve recruitment processes for families and increase enrollment. The parental experience of recruitment varied by enrollment status. These findings can guide future work aiming to inform optimal recruitment strategies for neonatal clinical trials.
AB - Objective: To describe the parental experience of recruitment and assess differences between parents who participated and those who declined to enroll in a neonatal clinical trial. Study design: This was a survey conducted at 12 US neonatal intensive care units of parents of infants who enrolled in the High-dose Erythropoietin for Asphyxia and encephaLopathy (HEAL) trial or who were eligible but declined enrollment. Questions assessed 6 factors of the parental experience of recruitment: (1) interactions with research staff; (2) the consent experience; (3) perceptions of the study; (4) decisional conflict; (5) reasons for/against participation; and (6) timing of making the enrollment decision. Results: In total, 269 of 387 eligible parents, including 183 of 242 (75.6%) of those who enrolled their children in HEAL and 86 of 145 (59.3%) parents who declined to enroll their children in HEAL, were included in analysis. Parents who declined to enroll more preferred to be approached by clinical team members rather than by research team members (72.9% vs 49.2%, P =.005). Enrolled parents more frequently reported positive initial impressions (54.9% vs 10.5%, P <.001). Many parents in both groups made their decision early in the recruitment process. Considerations of reasons for/against participation differed by enrollment status. Conclusions: Understanding how parents experience recruitment, and how this differs by enrollment status, may help researchers improve recruitment processes for families and increase enrollment. The parental experience of recruitment varied by enrollment status. These findings can guide future work aiming to inform optimal recruitment strategies for neonatal clinical trials.
KW - decisional conflict
KW - enrollment decision-making
KW - research participation
UR - http://www.scopus.com/inward/record.url?scp=85114906065&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2021.08.014
DO - 10.1016/j.jpeds.2021.08.014
M3 - Article
C2 - 34400207
AN - SCOPUS:85114906065
SN - 0022-3476
VL - 239
SP - 143-149.e3
JO - Journal of Pediatrics
JF - Journal of Pediatrics
ER -